Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Silvio Danese (Lead / Corresponding author), Severine Vermeire, Geert D'Haens, Julian Panés, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet, STARDUST study group, Craig Mowat (Contributing member)

Population Health and Genomics

Research output: Contribution to journal › Article › peer-review

65 Citations (Scopus)

65 Citations
1 Article

1 results

2022
Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))
Danese, S. (Lead / Corresponding author), Vermeire, S., D'Haens, G., Panés, J., Dignass, A., Magro, F., Nazar, M., Le Bars, M., Lahaye, M., Ni, L., Bravata, I., Lavie, F., Daperno, M., Lukáš, M., Armuzzi, A., Löwenberg, M., Gaya, D. R., Peyrin-Biroulet, L., STARDUST study group & Mowat, C. (Contributing member), 1 Feb 2022, In: The Lancet Gastroenterology and Hepatology. 7, 4, p. e8
Research output: Contribution to journal › Article › peer-review

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Research output

Search results

Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))